Pegcetacoplan: The Cyclic Peptide That Tamed Complement C3 - and Just Became the First Drug for Two Rare Kidney Diseases (July 3, 2026)
Table of Contents
From a lab peptide to a three-time approved drug
Most of the peptides that make headlines are experimental. Pegcetacoplan is the opposite: a peptide that has already crossed the finish line three separate times. It began life as compstatin, a small cyclic peptide discovered decades ago that binds complement component 3 (C3) - the central switchboard of the immune system's complement cascade. On its own, compstatin was too short-lived to be a drug. Apellis Pharmaceuticals engineered around that by taking an optimized compstatin analog (Cp05), making two copies of it, and tethering them to the two ends of a single 40-kilodalton polyethylene-glycol (PEG) chain. The PEG makes the peptide soluble and slows how fast the kidneys clear it, while the two-headed design lets each molecule grab two C3 molecules at once. The result - pegcetacoplan, once known as APL-2 - is now sold under three names for three very different diseases.
Why hitting C3 matters more than hitting C5
Complement can be blocked at different points. The best-known inhibitors, eculizumab and ravulizumab, act at the terminal step (C5), stopping the membrane-attack complex but leaving the earlier signal, C3b, free to coat cells. Pegcetacoplan works one step upstream, at C3 itself. That broader blockade shuts down all three complement pathways - classical, lectin and alternative - and stops both the membrane-attack complex and the C3b 'tagging' (opsonization) that marks cells for destruction. In paroxysmal nocturnal hemoglobinuria (PNH), that upstream position is the whole point: C5 inhibitors stop intravascular hemolysis but let C3b-coated red cells get destroyed elsewhere, so many patients stay anemic. In the head-to-head PEGASUS trial, pegcetacoplan beat eculizumab on hemoglobin - and earned its first FDA approval, as Empaveli, in May 2021.
The 2025 milestone: first drug for C3G and IC-MPGN
The newest and arguably most important chapter is in the kidney. C3 glomerulopathy (C3G) and primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN) are rare diseases in which the alternative complement pathway runs unchecked and dumps C3 into the kidney's filtering units, scarring them and often leading to kidney failure in young patients. Until 2025 there was no approved treatment. The Phase 3 VALIANT trial (NCT05067127) randomized 124 patients aged 12 and older to pegcetacoplan or placebo. It hit its primary endpoint with a 68% placebo-adjusted reduction in proteinuria, stabilized kidney function (an eGFR advantage of roughly 6.3 mL/min/1.73 m2 over placebo), and - strikingly - cleared the disease's fingerprint: 71% of treated patients reached zero C3 staining on kidney biopsy. On July 28, 2025 the FDA approved Empaveli for C3G and primary IC-MPGN in patients 12 and older, the first therapy ever cleared for these conditions. The results were published in the New England Journal of Medicine in December 2025.
The same molecule, reformulated for the eye
Complement overactivation isn't only a blood-and-kidney problem. In geographic atrophy - an advanced, blinding form of age-related macular degeneration - local complement activity is tied to the slow death of retinal cells. Apellis reformulated the very same peptide as an intravitreal (in-the-eye) injection called Syfovre, which in February 2023 became the first FDA-approved treatment for geographic atrophy, based on the DERBY and OAKS trials showing it slowed lesion growth. It's a useful reminder that one engineered peptide can be delivered systemically or locally to target the same biology in different organs. The eye formulation carries its own risks, including rare reports of retinal vasculitis, and is not interchangeable with the systemic infusion.
The trade-off: blocking complement lowers your guard
Complement exists to fight infection, so turning it down has a cost. Pegcetacoplan carries a boxed warning for serious infections from encapsulated bacteria - Neisseria meningitidis, Streptococcus pneumoniae and Haemophilus influenzae - and patients must be vaccinated and enrolled in a risk-management (REMS) program before starting. Common side effects in the kidney trial included injection-site reactions, fever, cold-like infections, cough and nausea. This is the same safety bargain shared across complement inhibitors, and it's why pegcetacoplan is a physician-administered prescription medicine, not something to be bought as a powder. It sits alongside other complement- and immune-targeting therapeutic peptides we cover, such as the C5 inhibitor zilucoplan and the immunomodulatory peptide efzofitimod.
Keeping it honest
Pegcetacoplan is a genuine success story for peptide engineering, but a few caveats are worth stating plainly. Its kidney approval rested largely on proteinuria and biomarker endpoints over a defined trial window; whether that translates into fewer patients reaching dialysis or transplant over many years still needs long-term follow-up. Broad complement inhibition is immunosuppressive and demands ongoing vigilance for infection. And nothing here is a do-it-yourself peptide - 'pegcetacoplan' or 'APL-2' sold as a research chemical is illegitimate and unsafe. What makes it worth knowing is the science: a small cyclic peptide, cleverly dimerized and PEGylated, that reached the clinic at the very center of the complement cascade and now helps patients across three separate diseases. This article is educational and not medical advice.
Ready to track your peptide research?
Open PepTracker ProPepTracker Pro Research Team
The PepTracker Pro Research Team is an editorial group of science writers, pharmacologists, and clinical researchers dedicated to making peptide science accessible. Every article is reviewed for accuracy against peer-reviewed sources and updated as new evidence emerges.
Citations
- [1] Trial of Pegcetacoplan in C3 Glomerulopathy and Immune-Complex MPGN (VALIANT) - NEJM (2025) Source
- [2] FDA Approves Apellis' EMPAVELI (pegcetacoplan) as the First C3G and Primary IC-MPGN Treatment for Patients 12 and Older (July 2025) Source
- [3] Pegcetacoplan versus Eculizumab in PNH (PEGASUS) - NEJM (2021) Source
- [4] Insight into mode-of-action and structural determinants of the compstatin family - Nature Communications (2022) Source
Related Articles
Zilucoplan (Zilbrysq): The Self-Injectable Peptide That Blocks Complement in Myasthenia Gravis (June 23, 2026)
Zilucoplan is a macrocyclic peptide that switches off the final step of the complement cascade. Unlike the IV antibodies that came before it, patients inject it under the skin once a day. Here is how it works and what the evidence shows.
Efzofitimod: A First-in-Class Immunomodulatory Peptide Aims to Take Sarcoidosis Patients Off Steroids (July 1, 2026)
Efzofitimod (ATYR1923) is a first-in-class immunomodulatory peptide that binds neuropilin-2 to calm lung inflammation in pulmonary sarcoidosis. Its Phase 3 EFZO-FIT trial missed its primary steroid-reduction endpoint in 2025 but showed benefit on symptoms and lung function — here is what it is, how it works, and where it stands in 2026.